Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022011084 - OXOPYRROLIDINE FPR2 AGONISTS

Publication Number WO/2022/011084
Publication Date 13.01.2022
International Application No. PCT/US2021/040798
International Filing Date 08.07.2021
IPC
C07D 207/273 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
207Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
02with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
18having one double bond between ring members or between a ring member and a non-ring member
22with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
24Oxygen or sulfur atoms
262-Pyrrolidones
273with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
C07D 401/04 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
04directly linked by a ring-member-to-ring- member bond
C07D 401/14 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14containing three or more hetero rings
C07D 407/14 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
407Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/183
14containing three or more hetero rings
C07D 413/14 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
413Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
14containing three or more hetero rings
C07D 487/04 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Applicants
  • BRISTOL-MYERS SQUIBB COMPANY [US]/[US]
Inventors
  • SHIRUDE, Pravin Sudhakar
  • RACHAMREDDY, Chandrasekhar Reddy
  • CHATTOPADHYAY, Amit Kumar
  • SESHADRI, Balaji
  • BALIGAR, Vishweshwaraiah
  • MADDURI, Sudhakara Reddy
  • KICK, Ellen K.
  • WURTZ, Nicholas R.
Agents
  • LIU, Hong
  • BARBIC, Andre
  • BELLOMY, Gregory R.
  • CLAUSS, Isabelle M.
  • COULTER, Kathryn
  • DELAUNEY, Ashton J.
  • FARQUHARSON-TORRES, Serena
  • GOLIAN, Paul D.
  • GREENBLATT, Gary D.
  • GUO, Z. Angela
  • HADAD, Henry
  • HAI, Bing
  • HAN, Bo
  • HICKEY, Denise
  • JACOBSEN, Barry H.
  • KORSEN, Elliott
  • LAUB, Friedrich Bernhard
  • LIU, Xiangyu
  • SUN, Jing G.
  • VANATTEN, Mary K.
  • VOM WEGE, Julia
  • WALSH, Brian J.
  • WENK, Melissa
Priority Data
63/049,83809.07.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) OXOPYRROLIDINE FPR2 AGONISTS
(FR) AGONISTES DE L'OXOPYRROLIDINE FPR2
Abstract
(EN) The disclosure relates to compounds of Formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
(FR) La divulgation concerne des composés de formule (I) qui sont des agonistes du récepteur 2 du peptide formylé (FPR2) et/ou des agonistes du récepteur 1 du peptide formylé (FPR1). La divulgation concerne également des compositions et des procédés d'utilisation des composés, par exemple pour le traitement de l'athérosclérose, de l'insuffisance cardiaque, de la bronchopneumopathie chronique obstructive (BPCO) et de maladies associées.
Latest bibliographic data on file with the International Bureau